Compare Sana Biotechnology Inc (SANA) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Vertiv Holdings Co — how do they compare? Sana Biotechnology Inc trades at $3.77 (market cap $1.01B), while Vertiv Holdings Co trades at $285.89 (market cap $103.99B). The key difference: Vertiv Holdings Co is far larger — about 103× Sana Biotechnology Inc's market cap, and Vertiv Holdings Co pays a 0.09% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | VRT | |
|---|---|---|
Market Cap | $1.01B | $103.99B |
Sector | Health | Technology |
52-Week High | $5.92 | $376.23 |
52-Week Low | $2.68 | $121.82 |
Enterprise Value | $980.22M | $104.21B |
Dividend Yield | — | 0.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.52, up 3.23% with a bullish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn improved in 2026. Recent positive developments include clinical data presentations and a $69M stock offering. Analyst consensus remains strong with 82% buy ratings and a $9.50 price target.
While SANA shows promising clinical progress and strong analyst support, significant financial losses and cash burn present substantial risks. The stock's upside potential depends on successful clinical trial outcomes and path to profitability, making it suitable for risk-tolerant investors seeking biotech exposure.
VRT trades at $272.40, down 1.01% on the day, with a bearish technical signal driven by moving averages and RSI levels near overbought territory. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.52 versus $1.43 expected, and revenue growth is supported by AI data center demand. Recent news highlights its role in AI infrastructure, though legal investigations pose a sentiment risk.
Outlook remains positive with a consensus price target of $386.58, reflecting 42% upside, driven by robust fundamentals and AI tailwinds. Risks include high valuation multiples, competitive pressures, and ongoing legal scrutiny. Investors should weigh growth potential against elevated P/E and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
